Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHVS, KURA, KNTE, SNDX, LYEL, and represent 100.00% of Foresite Capital Management IV's stock portfolio.
  • Added to shares of these 1 stock: PHVS (+$6.8M).
  • Reduced shares in these 3 stocks: Cymabay Therapeutics (-$27M), ACRS (-$19M), LYEL.
  • Sold out of its positions in ACRS, Cymabay Therapeutics.
  • Foresite Capital Management IV was a net seller of stock by $-40M.
  • Foresite Capital Management IV has $198M in assets under management (AUM), dropping by 9.93%.
  • Central Index Key (CIK): 0001704132

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Foresite Capital Management IV holds 5 positions in its portfolio as reported in the March 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pharvaris N V (PHVS) 47.2 $93M +7% 4.0M 23.11
 View chart
Kura Oncology (KURA) 19.9 $40M 1.8M 21.33
 View chart
Kinnate Biopharma (KNTE) 13.0 $26M 9.7M 2.66
 View chart
Syndax Pharmaceuticals (SNDX) 10.5 $21M 875k 23.80
 View chart
Lyell Immunopharma (LYEL) 9.4 $19M -5% 8.3M 2.23
 View chart

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017

View all past filings